[1]
2020. The IDEAL trial - a study protocol for a phase III randomized, double-blinded clinical trial assessing the ultra-short antibiotic prophylaxis of Isoniazid and Rifapentine in non-immunosuppressed patients with newly diagnosed latent tuberculosis. Principles and Practice of Clinical Research. 6, 1 (May 2020), 9–14.